Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Albert J Allen

Showing results (21-30 of 56) with videos related to

Pageof 6
Sort By:
Journal of Developmental and Behavioral Pediatrics : JDBP|August 17, 2004
Improvement in health-related quality of life in children with ADHD: an analysis of placebo controlled studies of atomoxetineAmy R Perwien, Douglas E Faries, Christopher J Kratochvil, et al.
Journal of Clinical Psychopharmacology|July 1, 2014
Executive function in adults with attention-deficit/hyperactivity disorder during treatment with atomoxetine in a randomized, placebo-controlled, withdrawal studyLenard Adler, Yoko Tanaka, David Williams, et al.
Drug Safety|March 28, 2008
Hepatic events associated with atomoxetine treatment for attention-deficit hyperactivity disorderMark E Bangs, Ling Jin, Shuyu Zhang, et al.
Journal of the American Academy of Child and Adolescent Psychiatry|January 8, 2008
Meta-analysis of suicide-related behavior events in patients treated with atomoxetineMark E Bangs, Sitra Tauscher-Wisniewski, John Polzer, et al.
Child and Adolescent Psychiatry and Mental Health|May 8, 2013
Baseline characteristics of European and non-European adult patients with attention deficit hyperactivity disorder participating in a placebo-controlled, randomized treatment study with atomoxetineHimanshu Upadhyaya, Lenard A Adler, Miguel Casas, et al.
The American Journal of Psychiatry|February 19, 2008
Atomoxetine and osmotically released methylphenidate for the treatment of attention deficit hyperactivity disorder: acute comparison and differential responseJeffrey H Newcorn, Christopher J Kratochvil, Albert J Allen, et al.
Clinical Pediatrics|May 8, 2009
Once-daily atomoxetine for treating pediatric attention-deficit/hyperactivity disorder: comparison of morning and evening dosingStan L Block, Douglas Kelsey, Daniel Coury, et al.
Postgraduate Medicine|September 3, 2015
Time-to-onset and -resolution of adverse events before/after atomoxetine discontinuation in adult patients with ADHDHimanshu Upadhyaya, Yoko Tanaka, Sarah Lipsius, et al.
Annals of Clinical Psychiatry : Official Journal of the American Academy of Clinical Psychiatrists|June 7, 2006
Safety and tolerability of once versus twice daily atomoxetine in adults with ADHDLenard Adler, Anthony Dietrich, Fred W Reimherr, et al.
Journal of the American Academy of Child and Adolescent Psychiatry|June 22, 2005
A randomized, placebo-controlled study of once-daily atomoxetine in the school setting in children with ADHDMargaret Weiss, Rosemary Tannock, Christopher Kratochvil, et al.
Pageof 6

Showing results (21-30 of 56) with videos related to

Sort By:
Pageof 6
Journal of Developmental and Behavioral Pediatrics : JDBP|August 17, 2004
Improvement in health-related quality of life in children with ADHD: an analysis of placebo controlled studies of atomoxetineAmy R Perwien, Douglas E Faries, Christopher J Kratochvil, et al.
Journal of Clinical Psychopharmacology|July 1, 2014
Executive function in adults with attention-deficit/hyperactivity disorder during treatment with atomoxetine in a randomized, placebo-controlled, withdrawal studyLenard Adler, Yoko Tanaka, David Williams, et al.
Drug Safety|March 28, 2008
Hepatic events associated with atomoxetine treatment for attention-deficit hyperactivity disorderMark E Bangs, Ling Jin, Shuyu Zhang, et al.
Journal of the American Academy of Child and Adolescent Psychiatry|January 8, 2008
Meta-analysis of suicide-related behavior events in patients treated with atomoxetineMark E Bangs, Sitra Tauscher-Wisniewski, John Polzer, et al.
Child and Adolescent Psychiatry and Mental Health|May 8, 2013
Baseline characteristics of European and non-European adult patients with attention deficit hyperactivity disorder participating in a placebo-controlled, randomized treatment study with atomoxetineHimanshu Upadhyaya, Lenard A Adler, Miguel Casas, et al.
The American Journal of Psychiatry|February 19, 2008
Atomoxetine and osmotically released methylphenidate for the treatment of attention deficit hyperactivity disorder: acute comparison and differential responseJeffrey H Newcorn, Christopher J Kratochvil, Albert J Allen, et al.
Clinical Pediatrics|May 8, 2009
Once-daily atomoxetine for treating pediatric attention-deficit/hyperactivity disorder: comparison of morning and evening dosingStan L Block, Douglas Kelsey, Daniel Coury, et al.
Postgraduate Medicine|September 3, 2015
Time-to-onset and -resolution of adverse events before/after atomoxetine discontinuation in adult patients with ADHDHimanshu Upadhyaya, Yoko Tanaka, Sarah Lipsius, et al.
Annals of Clinical Psychiatry : Official Journal of the American Academy of Clinical Psychiatrists|June 7, 2006
Safety and tolerability of once versus twice daily atomoxetine in adults with ADHDLenard Adler, Anthony Dietrich, Fred W Reimherr, et al.
Journal of the American Academy of Child and Adolescent Psychiatry|June 22, 2005
A randomized, placebo-controlled study of once-daily atomoxetine in the school setting in children with ADHDMargaret Weiss, Rosemary Tannock, Christopher Kratochvil, et al.
Pageof 6